Accelerating access for innovative medicines. An increasing number of innovative medicines are being approved based on data falling short of traditional Health System / Payer requirements. This challenge is wide-ranging, encompassing innovative medicines with short as well as chronic treatment regimes and a broad range of therapeutic indications and patient populations. In these circumstances: Health Systems / Payers seek a cautious approach to pricing based on a highly conservative view of patient benefit but are under pressure from Manufacturers to accept higher pricing with inherent financial risk; and Manufacturers seek to optimise pricing based on the patient benefit they expect a product to demonstrate in a real-world setting but are under pressure from Health Systems / Payers to accept lower pricing and uncertain returns. The current paradigm is to seek to resolve this gap in needs through negotiation on price rather than a systematic and fair framework which balances the interests of all parties. This can result in delays in market access (or no market access at all) thereby having profound consequences for health outcomes and R&D investment. Remedium was founded to tackle the affordability and risk related access challenges of innovative medicines using novel Value-based Payment Models which meet the needs of Health Systems / Payers and can be enhanced economically at Manufacturer discretion by using external capital. It is working in dialogue with Health Systems / Payers, Manufacturers and capital providers and is at the heart of the AIM4ALL Initiative encompassing some 84 million European patients. In addition to working with Health Systems / Payers and Manufacturers to break new ground, Remedium provides pre transaction co-ordination and post transaction management services.